hVIVO plc Directorate Change (0505U)
09 Juillet 2018 - 3:37PM
UK Regulatory
TIDMHVO
RNS Number : 0505U
hVIVO plc
09 July 2018
hVIVO plc
("hVIVO" or the "Company")
Directorate change
London, UK, 9 July 2018: hVIVO plc (AIM: HVO), a pioneer of
human disease models and an industry leading clinical development
services business, announces that, further to the statement issued
on 19 April 2018 in which it was announced that Kym Denny had
stepped down as CEO, Kym Denny is no longer a Director of the
Company and of its subsidiaries as of today's date.
- Ends -
For further information please contact:
hVIVO plc +44 207 756 1300
Trevor Phillips (Executive Chairman)
Fleur Wood (Director, Investor Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated
Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
About hVIVO plc
hVIVO plc ("hVIVO") is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 50 clinical studies,
inoculated over 2500 volunteers and has three first-in-class
therapies currently in development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFMGGNFLKGRZM
(END) Dow Jones Newswires
July 09, 2018 09:37 ET (13:37 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024